There’s a lot to be optimistic about in the Healthcare sector as 1 analysts just weighed in on and Nektar Therapeutics (NKTR) with bullish sentiments.
Nektar Therapeutics (NKTR)
William Blair analyst Andy Hsieh maintained a Buy rating on Nektar Therapeutics on October 27. The company’s shares closed last Tuesday at $15.77, close to its 52-week low of $13.63.
According to TipRanks.com, Hsieh is a 5-star analyst with an average return of 18.6% and a 58.9% success rate. Hsieh covers the Healthcare sector, focusing on stocks such as Viking Therapeutics, Seattle Genetics, and Beyondspring.
Currently, the analyst consensus on Nektar Therapeutics is a Moderate Buy with an average price target of $27.83, a 71.3% upside from current levels. In a report issued on October 27, Piper Sandler also maintained a Buy rating on the stock with a $35.00 price target.
See today’s analyst top recommended stocks >>
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
